MCID: SCR001
MIFTS: 40

Secretory Meningioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Secretory Meningioma

MalaCards integrated aliases for Secretory Meningioma:

Name: Secretory Meningioma 12 54 15 17 70
Meningioma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4588
MeSH 44 D008579
NCIt 50 C4718
SNOMED-CT 67 253081009
UMLS 70 C0025286 C1384406

Summaries for Secretory Meningioma

MalaCards based summary : Secretory Meningioma, also known as meningioma, is related to signet ring cell adenocarcinoma and meningothelial meningioma. An important gene associated with Secretory Meningioma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways is Cytoskeletal Signaling. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and spinal cord, and related phenotype is Increased proliferation.

Related Diseases for Secretory Meningioma

Diseases related to Secretory Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 signet ring cell adenocarcinoma 29.9 MUC1 KRT7 CEACAM5
2 meningothelial meningioma 29.5 TRAF7 SMARCE1 SERPINA3 NF2
3 meningioma, familial 29.1 VIM TRAF7 SMARCE1 SMARCB1 SERPINA3 NF2
4 intracranial meningioma 10.6
5 lymphoplasmacyte-rich meningioma 10.6
6 perineurioma 10.4 VIM MUC1
7 papillary tumor of the pineal region 10.4 VIM MUC1
8 endometrial mucinous adenocarcinoma 10.4 VIM MUC1
9 scrotum paget's disease 10.4 MUC1 KRT7
10 cutaneous leiomyosarcoma 10.4 VIM MUC1
11 gallbladder signet ring cell adenocarcinoma 10.4 MUC1 KRT7
12 pericardial mesothelioma 10.4 VIM MUC1
13 mucinous intrahepatic cholangiocarcinoma 10.3 MUC1 KRT7
14 middle ear adenoma 10.3 MUC1 KRT7
15 reticulum cell sarcoma 10.3 VIM MUC1
16 benign metastasizing leiomyoma 10.3 VIM KRT7
17 glandular cystitis 10.3 MUC1 KRT7
18 cystadenofibroma 10.3 MUC1 KRT7
19 ossifying fibromyxoid tumor 10.3 VIM MUC1
20 mucinous tubular and spindle renal cell carcinoma 10.3 MUC1 KRT7
21 polymorphous low-grade adenocarcinoma 10.3 VIM MUC1
22 solid adenocarcinoma with mucin production 10.3 MUC1 KRT7
23 ovarian serous cystadenofibroma 10.3 MUC1 KRT7
24 biphasic synovial sarcoma 10.3 VIM MUC1
25 epithelioid trophoblastic tumor 10.3 MUC1 KRT7
26 endosalpingiosis 10.3 MUC1 KRT7
27 mixed fibrolamellar hepatocellular carcinoma 10.3 MUC1 KRT7
28 dendritic cell tumor 10.3 VIM MUC1
29 intravascular papillary endothelial hyperplasia 10.3 VIM SERPINA3
30 bladder leiomyoma 10.3 VIM KRT7
31 congenital epulis 10.3 VIM SERPINA3
32 epulis 10.3 VIM SERPINA3
33 adenoid squamous cell carcinoma 10.3 VIM KRT7
34 renal pelvis carcinoma 10.3 KRT7 CEACAM7
35 malignant peritoneal mesothelioma 10.3 NF2 MUC1
36 multicentric reticulohistiocytosis 10.3 VIM SERPINA3
37 adenomyoma 10.3 MUC1 KRT7
38 granulosa cell tumor of the ovary 10.3 VIM KRT7
39 nephrogenic adenoma 10.3 MUC1 KRT7
40 odontogenic myxoma 10.3 VIM SERPINA3
41 gastric squamous cell carcinoma 10.3 SERPINA3 KRT7
42 sclerosing hemangioma 10.2 MUC1 KRT7
43 osteofibrous dysplasia 10.2 VIM MUC1
44 vulvar eccrine porocarcinoma 10.2 MUC1 CEACAM5
45 embryonal sarcoma 10.2 VIM SERPINA3
46 nodular tenosynovitis 10.2 VIM SERPINA3
47 pediatric meningioma 10.2 TRAF7 NF2
48 parachordoma 10.2 VIM MUC1 KRT7
49 bile duct adenoma 10.2 VIM MUC1 KRT7
50 spiradenoma 10.2 VIM MUC1 KRT7

Graphical network of the top 20 diseases related to Secretory Meningioma:



Diseases related to Secretory Meningioma

Symptoms & Phenotypes for Secretory Meningioma

GenomeRNAi Phenotypes related to Secretory Meningioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

Drugs & Therapeutics for Secretory Meningioma

Drugs for Secretory Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
7 Fibrin Tissue Adhesive Phase 4
8 Neurotransmitter Agents Phase 4
9 Coagulants Phase 4
10 Antifibrinolytic Agents Phase 4
11 Hemostatics Phase 4
12 Anesthetics Phase 4
13 Anesthetics, Local Phase 4
14 Vasoconstrictor Agents Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Adrenergic beta-Agonists Phase 4
17 Respiratory System Agents Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Epinephryl borate Phase 4
20 Mydriatics Phase 4
21 Sympathomimetics Phase 4
22 Adrenergic Agents Phase 4
23 Adrenergic Agonists Phase 4
24 Bronchodilator Agents Phase 4
25
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
26
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
28
Cisatracurium Approved Phase 3 96946-41-7 62887
29
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
32
Aminolevulinic acid Approved Phase 3 106-60-5 137
33 Contraceptives, Postcoital Phase 3
34 Contraceptives, Oral Phase 3
35 Progestins Phase 3
36 Contraceptive Agents Phase 3
37 Antihypertensive Agents Phase 3
38 Photosensitizing Agents Phase 3
39 Dermatologic Agents Phase 3
40
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
41
Hydroxyurea Approved Phase 2 127-07-1 3657
42
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
43
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
44
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
45
Verapamil Approved Phase 2 52-53-9 2520
46
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
47
Mesna Approved, Investigational Phase 2 3375-50-6 598
48
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
49
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
50
carbamide peroxide Approved Phase 2 124-43-6

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction Not yet recruiting NCT04756050 Phase 4 Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
7 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
12 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
13 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
14 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Unknown status NCT01849484 Phase 2
15 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
16 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
17 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
18 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
19 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
20 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Completed NCT00006119 Phase 2 hydroxyurea
21 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
22 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
23 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
24 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
25 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
26 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
27 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
28 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
29 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
30 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
31 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
32 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
33 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
34 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
35 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
36 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
37 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
38 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
39 A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma Recruiting NCT04659811 Phase 2 Pembrolizumab
40 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
41 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
42 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
43 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
44 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
45 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
46 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
47 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
48 Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors Recruiting NCT03273712 Phase 2 Amino Acids
49 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Active, not recruiting NCT00895622 Phase 2
50 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Active, not recruiting NCT00626730 Phase 2

Search NIH Clinical Center for Secretory Meningioma

Genetic Tests for Secretory Meningioma

Anatomical Context for Secretory Meningioma

MalaCards organs/tissues related to Secretory Meningioma:

40
Brain, Pituitary, Spinal Cord, Bone, Breast, Pineal, Endothelial

Publications for Secretory Meningioma

Articles related to Secretory Meningioma:

(show top 50) (show all 15063)
# Title Authors PMID Year
1
[A rare case of tumor-to-tumor metastasis: secondary deposits of pulmonary adenocarcinoma in a secretory meningioma]. 61 54
12368922 2002
2
Pseudopsammomatous meningioma with elevated serum carcinoembryonic antigen: a true secretory meningioma. Case report. 54 61
1984492 1991
3
Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells. 61
33622177 2021
4
Case report 68Ga-DOTATATE of optic nerve sheath meningioma. 61
33748535 2021
5
KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. 61
33652084 2021
6
Proton therapy: A therapeutic opportunity for aggressive pediatric meningioma. 61
33682333 2021
7
Intracranial long-term complications of radiation therapy: an image-based review. 61
33392738 2021
8
The Stanford stereotactic radiosurgery experience on 7000 patients over 2 decades (1999-2018): looking far beyond the scalpel. 61
33799297 2021
9
Cognitive reserve protects language functions in patients with brain tumours. 61
33524456 2021
10
A cohort study on adult hematological malignancies and brain tumors in relation to magnetic fields from indoor transformer stations. 61
33601135 2021
11
Demographic and socioeconomic disparities of benign and malignant spinal meningiomas in the United States. 61
33068594 2021
12
Case report of primary dural lymphoma mimicking a cerebellar meningioma and brief review of literature. 61
31301042 2021
13
The histopathological diagnosis of atypical meningioma: glass slide versus whole slide imaging for grading assessment. 61
33305338 2021
14
Postpartum Recovery From Meningioma-Related Oculomotor Palsy. 61
33706360 2021
15
Effect of Surgeon Experience on Surgical Outcome of 80-Year-Old or Older Intracranial Meningioma Patients. 61
33422717 2021
16
A rare case of parasagittal meningioma causing isolated foot drop: case report and review of the literature. 61
31786742 2021
17
Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. 61
33528717 2021
18
In-Hospital Complications After Surgery in Elderly Patients with Asymptomatic or Minor Symptom Meningioma: A Nationwide Registry Study. 61
33444840 2021
19
Orbital decompressive effect of endoscopic transorbital surgery for sphenoorbital meningioma. 61
33226438 2021
20
Trends in the Management Paradigms of Intracranial Meningioma. 61
33777636 2021
21
Clinical Outcome and Recurrence After Meningioma Surgery: An Experience from a Developing Country, Nepal. 61
33359878 2021
22
Cavernous Sinus Meningioma Resection Through Orbitozygomatic Craniotomy. 61
33515796 2021
23
Late malignant transformation of anaplastic meningioma 18 years after primary surgery: A case report. 61
33775317 2021
24
Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. 61
32859705 2021
25
Intraparenchymal supratentorial papillary meningioma: a case report. 61
29564936 2021
26
Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy. 61
33190809 2021
27
[Retracted] α3β1 integrin promotes radiation-induced migration of meningioma cells. 61
33655324 2021
28
Novel histopathological classification of meningiomas based on dural invasion. 61
32546547 2021
29
Value of KI-67/MIB-1 labeling index and simpson grading system to predict the recurrence of who grade I intracranial meningiomas compared to who grade II. 61
33775343 2021
30
Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience. 61
33449307 2021
31
WHO classification of meningiomas-A single institutional experience. 61
33144180 2021
32
Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. 61
33741867 2021
33
Neurosarcoidosis Masquerading as Giant Cell Arteritis With Incidental Meningioma. 61
32441899 2021
34
Anterior Petrosal [Kawase] Approach to Meckel's Cave Meningioma: 2-Dimensional Operative Video. 61
33475720 2021
35
Uveal Melanoma Metastatic to the Cavernous Sinus: A Case Report. 61
32732542 2021
36
SWI/SNF deficient central nervous system neoplasms. 61
33762087 2021
37
Metastases to meningioma-review and meta-analysis. 61
33389125 2021
38
Can Ophthalmologic Examination Predict Abducens Nerve Recovery After Endoscopic Skull Base Surgery? 61
32809233 2021
39
Chordoma and meningioma arising as a collision tumor in the petroclival region: Case report and literature review. 61
33749579 2021
40
Risk factor for cerebrospinal fluid leak after endoscopic endonasal skull base surgery: a single-center experience. 61
33733997 2021
41
Imaging Characteristics and Surgical Outcomes in Patients With Intraspinal Solitary Fibrous Tumor/Hemangiopericytoma: A Retrospective Cohort Study. 61
33691508 2021
42
Aberrant expression of thyroid transcription factor-1 in meningeal solitary fibrous tumor/hemangiopericytoma. 61
33666786 2021
43
Deep learning approaches for automated classification and segmentation of head and neck cancers and brain tumors in magnetic resonance images: a meta-analysis study. 61
33666859 2021
44
Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas. 61
33716047 2021
45
Clinical outcome after microsurgical resection of intraventricular trigone meningiomas: a single-centre analysis of 20 years and literature overview. 61
32772161 2021
46
The Prognostic Value of Methylation Signatures and NF2 Mutations in Atypical Meningiomas. 61
33809258 2021
47
The Zap-X Radiosurgical System in the Treatment of Intracranial Tumors: A Technical Case Report. 61
33442727 2021
48
Approach to patient with unilateral optic disc edema and normal visual function. 61
33799215 2021
49
Gaze-evoked amaurosis from idiopathic orbital inflammation. 61
33781156 2021
50
Machine learning may predict individual hand motor activation from resting-state fMRI in patients with brain tumors in perirolandic cortex. 61
33758954 2021

Variations for Secretory Meningioma

Expression for Secretory Meningioma

Search GEO for disease gene expression data for Secretory Meningioma.

Pathways for Secretory Meningioma

Pathways related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 VIM NF2 MUC1 KRT7

GO Terms for Secretory Meningioma

Cellular components related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SWI/SNF complex GO:0016514 9.16 SMARCE1 SMARCB1
2 nBAF complex GO:0071565 8.96 SMARCE1 SMARCB1
3 npBAF complex GO:0071564 8.62 SMARCE1 SMARCB1

Biological processes related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleosome disassembly GO:0006337 8.96 SMARCE1 SMARCB1
2 positive regulation of histone H4 acetylation GO:0090240 8.62 SMARCB1 MUC1

Sources for Secretory Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....